Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats

Human Gene Therapy

Volumn 7, Issue 8, 1996, Pages 901-911

  Chao, Julie ^a   Jin, Lan ^a   Chen, Li Mei ^a   Chen, Vincent C ^a   Chao, Lee ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; METALLOTHIONEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; EXPRESSION VECTOR; FEMALE; GENE; GENE SEQUENCE; GENE TARGETING; HYPERTENSION; KALLIKREIN KININ SYSTEM; LONG TERMINAL REPEAT; MALE; NONHUMAN; PORTAL VEIN; PROMOTER REGION; RAT; ROUS SARCOMA ONCOVIRUS; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0029971216     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.8-901     Document Type: Article

References (43)

1. ADER, J.L., POLLOCK, D.M., BUTTERFIELD, M.I., and ARENDSHORST, W.J. (1985). Abnormalities in kallikrein excretion in spontaneously hypertensive rats. Am. J. Physiol. 248 (3 Pt. 2), F396-F403.
2. BELLINI, C., FERRI, C., PICCOLI, A., CORLOMAGNO, A., FRANCESCO, L-DI, BONAVITA, M.S., SANTUCCI, A., and BALSANO, F. (1993). The influence of salt-sensitivity on the blood pressure response to exogenous kallikrein in essential hypertensive patients. Nephron 65, 28-35.
3. BERRY, T.D., HASSTEDT, S.J., HUNT, S.C., WU, L.L., SMITH, J.B., ASH, K.O., KUIDA, H., and WILLIAMS, R.R. (1989). A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 13, 3-8.
4. BHOOLA, K.D., FIGUEROA, C.D., and WORTHY, K. (1992). Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44, 1-8.
5. CAMPBELL, D.J., DUNCAN, A-M, KLADIS, A., and HARRAP, S.B. (1995). Increased levels of bardykinin and its metabolites in tissues of young spontaneously hypertensive rats. J. Hypertension 13, 739-746.
6. CLEMENTS, J.A. (1989). The glandular kallikrein family of enzymes: tissue-specific expression and hormonal regulation. Endocrine Rev. 10, 393-419.
7. ELLIOT, R., and NUZUM, F.R. (1934). The urinary excretion of a depressor substance (kallikrein of Frey and Kraut) in arterial hypertension. Endocrinology 18, 462-474.
8. FAVARO, S., BAGGIO, B., ANTONELLO, A., ZEN, A., CANNELLA, G., TODESCO, S., and BORSATTI, A. (1975). Renal kallikrein content of spontaneously hypertensive rats. Clin. Sci. Mol. Med. 49, 69-71.
9. FLOTTE, T.R. (1993). Prospects for virus-based gene therapy for cystic fibrosis. J. Bioenerg. Biomembr. 25, 37-42.
10. GARRETT, J.R., CHAO, J., PROCTOR, G.B., C. WANG, C., ZHAANG, X.S., CHAN, K.-M., and SHORI, D.K. (1995). Influences of secretorya cavities in rat submandibular glands on tissue kallikrein circulating in the blood. Exp. Phys. 80, 429-440.
11. GELLER, R.G., MARGOLIUS, H.A., PISANO, J.J., and KEISER, H.R. (1975). Urinary kallikrein excretion in spontaneously hypertensive rats. Circ. Res. 36 (6 Suppl. 1), 103-106.
12. GILKESON, G.S., BLOOM, D.D., PISETSKY, D.S., and CLARKE, S.H. (1993). Molecular characterization of anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. Differences from spontaneous anti-DNA in the content and location of VH CDR3 arginines. J. Immunol. 15, 1353-1364.
13. GLANVILLE, N., DURNAM, D.M., and PALMITER, R.D. (1981). Structure of mouse metallothionein-1 gene and its mRNA. Nature 292, 267-269.
14. LIN, F.K., CHAO, J., and L. CHAO. (1995). Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension (in press).
15. LINZ, W., WIEMER, G., GOHLKE, P., UNGER, T., and SCHOLKENS, B.A. (1995). Contribution of kinins to the cardiovascular actions of angiotension-converting enzyme inhibitors. Pharmacol. Rev. 47, 25-49.
16. LOWRY, O.H., ROSEBROUGH, N.J., FARR, A.L., and RANDALL, R.I. (1951). Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265-275.
17. MADEDDU, P., GHELI, T., BACCIU, P.P., MAIOLI, M., and GLORIOSO, N. (1993). A kallikrein-like enzyme in human vascular tissue. Am. J. Hypertens. 6, 344-348.
18. MARGOLIUS, H.S. (1989). Tissue kallikreins and kinins: regulation and roles in hypertensive and diabetic diseases. Annu. Rev. Pharmacol. Toxicol. 29, 343-364.
19. MARGOLIUS, H.S., GELLER, R., DE JONG, W., PISANO, J.J., and SJOERDSMA, A. (1971). Altered urinary kallikrein excretion in human hypertension. Lancet 2, 1063-1065.
20. MARGOLIUS, H.S., GELLER, R., DE JONG, W., PISANO, J.J., and SJOERDSMA, A. (1972). Altered urinary kallikrein excretion in rats with hypertension. Circ. Res. 30, 358-362.
21. MARGOLIUS, H.S., HORWITZ, D., PISANO, J.J., and KEISER, H.R. (1974). Urinary kallikrein excretion in hypertensive man. Relationships to sodium intake and sodium-retaining steroids. Circ. Res. 35, 820-825.
22. MULLIGAN, R.C. (1993). The basic science of gene therapy. Science 260, 926-932.
23. NOLLY, H., SCICLI, A.G., and SCICLI, G. (1985). Characterization of a kininogenase from rat vascular tissue resembling tissue kallikrein. Circ. Res. 56, 816-821.
24. NOLLY, H., CARBINI, L.A., SCICLI, G., CARRETERO, O.A., and SCICLI, A.G. (1994). A local kallikrein-kinin system is present in rat hearts. Hypertension 23, 919-923.
25. OGAWA, K., ITO, T., BAN, M., MOCHIZUKI, M., and SATAKE, T. (1985). Effects of orally administered glandular kallikrein on urinary kallikrein and prostaglandin excretion, plasma immunoreactive prostanoids and platelet aggregation in essential hypertension. Klin Wochenschr, 63, 332-336.
26. OVERLACK, A., STUMPE, K.O., KOLLOCH, R., RESSEL, C., and KRUECK, F. (1981). Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Results of double blind study. Hypertension. 3 (3 Pt. 2), 118-121.
27. OZA, N.B., and GOUD, H.D. (1992). Kininogenase of the aortic wall in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 20 (Suppl. 9); S1-S3.
28. PRAVENEC, M., KEN, V., KUNES, J., SCICLI, G., CARRETERO, O.A., SIMONET, L., and KURTZ, T.W. (1991). Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension 17, 242-246.
29. ROLLIER, A., DIPERSIO, C.M., CEREGHINI, S., STEVENS, K., TRONICHE, F., ZARET, K., and WEISS, M.C. (1993). Regulation of albumin gene expression in hepatoma gene of fetal phenotype: Dominant inhibition of HNF1 function and role of ubiquitous transcription factors. Mol. Biol. Cell 4, 59-69.
30. SAED, G.M., CARRETERO, O.A., and MACDONALD, R. (1990). Kallikrein messenger RNA in rat arteries and veins. Circ. Res. 67, 510-516.
31. SCICLI, A.G., and CARRETERO, O.A. (1986). Renal kallikrein-kinin system. Kid. Internatl. 29, 120-130.
32. SHIMAMOTO, K., CHAO, J., and MARGOLIUS, H.S. (1982). A method for determination of human urinary inactive kallikrein (prekallikrein). Tohoku. J. Exp. Med. 137, 269-274.
33. SHIMAMOTO, K., H.S., MARGOLIUS, H.S., CHAO, J., and KAPLAN, A.P. (1984). The measurement of immunoreactive glandular kallikrein in human serum and its clinical application. J. Lab. Clin. Med. 103, 731-738.
34. SONG, Q., CHAO, J., and CHAO, L. (1996). High-level expression of human tissue kallikrein in the circulation induces hypotension in transgenic mice. Immunopharmacology (in press).
35. UNGER, T., and RETTIG, R. (1990). Development of genetic hypertension. Is there a "critical phase"? Hypertension 16, 615-616.
36. WANG, C., CHAO, L., and CHAO, J. (1995). Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J. Clin. Invest. 95, 1710-1716.
37. WANG, J., XIONG, W., YANG, Z., DAVIS, T., DEWEY, M.J., CHAO, J., and CHAO, L. (1994). Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 23, 236-243.
38. WILSON, J.M., GROSSMAN, M., WU, C.H., CHOWDHURY, N.R., WU, G.Y., and CHOWDHURY, J.R. (1992a). Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits. J. Biol. Chem. 267, 963-967.
39. WILSON, J.M., GROSSMAN, M., CABRERA, J.A., WU, C.H., and WU, G.Y. (1992b). A novel mechanism for achieving transgene persistence in vivo after somatic gene transfer into hepatocytes. J. Biol. Chem. 267, 11483-11489.
40. WOODLEY-MILLER, C., CHAO, J., and CHAO, L. (1989). Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. J. Hypertens. 7, 865-871.
41. WU, G.Y., WILSON, J.M., SHALABY, F., GROSSMAN, M., SHAFRITZ, D.A., and WU, C.H. (1991). Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in Nagase rats. J. Biol. Chem. 266, 14338-14342.
42. XIONG, W., CHAO, J., and CHAO, L. (1995). Muscle delivery of human tissue kallikrein gene reduces blood pressure in spontaneously hypertensive rats. Hypertension 25 (part 2), 715-719.
43. ZINNER, S.H., MARGOLIUS, H.S., ROSNER, B., and KASS, E.H. (1978). Stability of blood pressure rank and urinary kallikrein concentration in childhood: An eight year follow-up. Circulation 58, 908-915.